Business Wire

MAVENIR/MOBILEDGEX

22.6.2021 15:02:08 CEST | Business Wire | Press release

Share
Mavenir and MobiledgeX Enable Global Edge Connectivity With Deutsche Telekom

Mavenir, in collaboration with MobiledgeX and Deutsche Telekom, have demonstrated and validated the reference design for deploying cloud-native 5G User Plane Function (UPF) to support Multi-Access Edge Computing (MEC) applications, tailored to each use case need for proximity and performance. The reference design is fully cloud-native, abstracted away from underlying cloud architecture, infrastructure vendor and operating owner.

“We are excited to partner with Mavenir and MobiledgeX to demonstrate dynamic cloud-native deployment of 5G Core UPF for users where it is needed. The UPF can run inside the operator’s owned network, inside a private 4G/5G network, inside the roaming network, or in the public cloud. The ability to dynamically and seamlessly orchestrate traffic across our own footprint and the footprint of others opens up the possibility for new connectivity solutions for customers,” says Alex Choi, SVP Strategy & Technology Innovation, Deutsche Telekom.

A service-based, cloud-native UPF is at the core of the reference design. Since the introduction of mobile packet data in 3G, all data traffic, irrespective of source, destination, and requesting application, has been tunneled back to a limited number of fixed (packet gateway) anchor points inside the mobile networks. This is increasingly inefficient, non-performant, and prone to bottlenecks. 5G Core standards enable dynamic placement of the anchor point (the UPF) based on the application and network’s needs. The combination of Mavenir’s widely deployed 4G/5G cloud-native Converged Packet Core solution, coupled with the MobiledgeX Edge-Cloud platform enables the UPF to be placed on different clouds from different vendors with different ownership. Service provider control, security, and privacy are maintained by a customer’s owning operator at all times, even when roaming. This architecture helps optimal placement of the application’s backend servers, enabling a superior user experience and increased network efficiency, by significantly reducing the distance the data needs to travel before it is processed.

Validated Reference Design

For this trial validation, the Mavenir 5G Core is running in Deutsche Telekom’s network. Two network and vendor-independent cloudlets, located in Germany, have been deployed as valid UPF placements in the 5G Core routing. For instance, a video application is started on a 5G phone connected to Deutsche Telekom’s 5G network in Berlin. The request is sent to the 5G Core that selects UPF placement in the Berlin cloudlet. Tunneling is established. The video request is passed to the local edge-placed video cache and delivery commences. The identical request is made in Hanover. The traffic is then established to the Hanover cloudlet and local fulfillment occurs there. The MobiledgeX Edge Cloud 3.0 platform dynamically controls the secure placement, lifecycle management, and video traffic routing of the edge-based UPF and the video application.

“This is a successful milestone for cloud-native 5G Core traffic routing, giving Deutsche Telekom the freedom to deliver a point of interconnect/local breakouts anywhere in the world, on any cloud,” says Bejoy Pankajakshan, Chief Strategy Officer, Mavenir. “Cloud-native design of 5G network functions integrated with orchestration tools makes it possible to achieve a new level of flexibility in network function placement. Automation, agility, and flexibility are at the heart of this project.”

“The MobiledgeX Edge-Cloud platform enables our operator customers to dynamically manage and allocate UPF functionality across their own cloud infrastructure independent of vendor, in roaming partners mobile networks, in private 4G/5G networks, and in public clouds, all through one pane of glass and in one trusted and secure operation,” says Sunay Tripathi, Chief Technology Officer & EVP of Engineering & Product, MobiledgeX. “Cloud-native UPF operation transforms traffic patterns in mobile operator networks, making the telecom operator the largest customer of their own edge cloud offering which is necessary to be a true cloud leader. We are very excited that Deutsche Telekom has taken the initiative to lead.”

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

About MobiledgeX

MobiledgeX is working with global mobile operators to deliver full control over multi-cloud edge deployments. The company’s MobiledgeX Edge-Cloud platform provides a common interface for managing application workloads anywhere, abstracted from underlying infrastructure, to maintain control over data, privacy and security. It also provides device native SDK and matching engines for operator and third-party application developers to maximize performance and efficiency for cloud-native applications at the edge. MobiledgeX Edge-Cloud is proven in market today via trials, proofs of concepts and deployments that involve more than 20 global operators and a range of next-gen app developers.

MobiledgeX is an edge computing company founded by Deutsche Telekom AG and headquartered in San Jose, California. https://mobiledgex.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye